Adult w/ insufficiently controlled type 2 DM as an adjunct to diet & exercise in addition to metformin, metformin & sulphonylurea, & metformin & basal insulin or Na-glucose cotransporter 2 (SGLT2) inhibitor.
Inj SC in the abdomen, in the thigh or in the upper arm. Initially 0.25 mg once wkly. After 4 wk, increase dose to 0.5 mg once wkly. After at least 4 wk w/ 0.5 mg once wkly, dose can be increased to 1 mg once wkly to further improve glycaemic control. Wkly doses >1 mg are not recommended.
Not to be administered IV or IM. Not to be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Discontinue if pancreatitis is suspected & not to be restarted if confirmed. Not recommended for patients w/ CHF NYHA Class IV. Consider GI adverse reactions in patients w/ impaired renal function. Increased risk of hypoglycaemia in combination w/ a sulfonylurea or insulin. Patients w/ diabetic retinopathy treated w/ insulin. Not recommended for use in patients w/ ESRD. Experience in patients w/ severe hepatic impairment is limited. Women of childbearing potential are recommended to use contraception. Not to be used during pregnancy & breast-feeding. No safety & efficacy data available in childn & adolescents <18 yr. Limited therapeutic experience in elderly ≥75 yr.
Potential to impact the rate of absorption of concomitantly administered oral medicinal products. Frequent INR monitoring w/ warfarin or other coumarin derivatives.
Sign Out
